Results Staphylococcus aureus and coagulase negative staphylococci were the two most common organisms isolated. Resolution of the ulcer was achieved in 93% and 87% of cases in the ofloxacin and control groups respectively.
Bacterial infection of the cornea produces a wide spectrum of clinical signs and symptoms ranging from small peripheral superficial keratitis to deep corneal stromal ulcerations. Early diagnosis and prompt and adequate therapy is essential to eradicate the infectious agents, to prevent tissue damage and to minimise scarring or melting. 1 This further helps in preservation of the vision with maintenance of near-normal tissue integritythe ultimate goal for therapy of infectious keratitis. Many antibiotics have been used in the past for treatment of bacterial keratitis. Several in vitro studies suggest that many bacteria are becoming resistant to commonly used antibiotics. Therefore there is a need to study the efficacy of newer antibiotics as and when demanded.
Ofloxacin, a new fluoroquinolone, is an anti infective agent with potency against a wide range of gram-positive and gram-negative bacteria and obligate anaerobes? Though a number of studies have been reported from western countries, no such trial has been conducted in India, perhaps due to non availability of the drugs on the Indian market. Recently, though the drug has not come to market, it has been prepared and tested by an Indian company, Ranbaxy. To the best of our knowledge there are no published reports from India about its efficacy. We undertook a clinical trial to assess the clinical efficacy of topical ofloxacin 0.3% for the treatment of bacterial keratitis in a prospective double-masked, randomised, comparative manner versus a combination of fortified ophthalmic solutions of cefazolin sodium 50 mg/ml and tobramycin sulphate 1.5%.
Patients and methods
Patients who were suffering from bacterial keratitis and attended the Corneal service of Dr Rajendra Prasad Centre for Ophthalmic Sciences for treatment were included in the study. All the Eye (1999) 13, 744-747 © 1999 Royal College of Ophthalmologists
Duration (in days) patients who had both smear and culture positivity for bacteria were enrolled in the study. Topical ofloxacin, saline, tobramycin and cefazolin were packaged in identical plastic bottles and labelled as 1 to 4. Details of the actual formulations were kept in a sealed flap until the end of the study. All 30 patients were randomised to receive either one bottle of ofloxacin and one bottle of normal saline solution (1 + 2) or one bottle of 1.5% tobramycin solution and 5% cefazolin solution (3 + 4). The drug instillation protocol was one drop of each of the two solutions every 30 min for 6 h, 1 hourly on days 1-3,2 hourly on days 4-5 and then 4 hourly until 1 week after complete resolution of the ulcer. A 5 min interval was allowed between the two drops and the drugs were instilled during the patients' waking time. Additional supportive treahnent included vitamins, cycloplegic and anti-glaucoma therapy.
Clinical response to the therapy was monitored daily at the slit lamp until complete resolution. At each examination the degree of change in the epithelial defect relative to the baseline was assessed by fluorescein staining, infiltrate, aqueous flare and cells, and ciliary congestion. Subjective improvement in visual acuity and symptomatic relief were also noted. Resolution of the corneal ulcer was defined by improvement in visual acuity, complete re-epithelisation with non-progression of the stromal infiltrates, disappearance of corneal oedema and increased visualisation of iris details.
Statistical analysis
Comparisons between the study group and controls were made by Student's t-test.
Results
The age range of the ofloxacin group was 15-70 years while that of the control group was 14-72 years (Table 1) . In both groups the M:F ratio was 3:2 ( Table 1 ). The most frequent organism isolated in both the groups was coagulase-negative staphylococcus and Staphylococcus aureus ( Table 2 ). All the ulcers were of grade ill with average epithelial defect size of 36.306 ± 3.57 mm 2 and 35.756 ± 4.80 mm 2 in the ofloxacin and control groups respectively (Table 1) . Six eyes from the ofloxacin group and 7 from the control group had a history of prior trauma and in 2 eyes from each group topical steroid use caused the ulcer; one eye from each group had contact lens-induced ulcer. The average time required for symptomatic relief was 7.8 ± 1.54 days (range 6-10 days) in the ofloxacin group compared with 8.33 ± 1.54 days (range 5-10 days) in the control group (Fig. 1) . The difference between the two was statistically significant Fig. 2) . The difference between the two groups was again statistically not significant (p = 0.46). One eye from the ofloxacin group and 2 eyes from the control group remained refractory at the end of 4 weeks despite early symptomatic relief; for these eyes therapeutic penetrating keratoplasty was carried out. Almost all the eyes in both groups had a pre-treatment visual acuity of PL,PR to counting fingers, which improved to counting fingers to 20/60 in the ofloxacin group and counting fingers to 20/80 in the control group (Table 3) 3 months after resolution. Residual full thickness corneal opacity 3 months after resolution was observed in only 2 eyes of the ofloxacin group as against 3 eyes of the control group (Table 1) . No ocular or systemic side-effects were encountered in any of the patients from either group.
Discussion
One of the most important principles in the management of infective keratitis is the initiation of an early and effective antimicrobial drug with the least toxicity. Based on the results from a comparative study with that of tobramycin and cefazolin, they further reported the safety of 0.3% ofloxacin? However, to date no published report is available in the Indian literature, In the present comparative, randomised prospective study we selected only grade III ulcers of moderate severity, We did not include either mild or severe-grade cases: a mild degree of ulcer may not provide good information because of its quick response to treatment and a severe grade may require additional medical! surgical therapy. Combined therapy of topical fortified tobramycin 1.5% and cefazolin 5% was used as control as these two drugs are used worldwide for the management of bacterial keratitis. The data analysis of our study revealed that trauma was the most frequent factor responsible for bacterial keratitis, which was in agreement with the previous studies.9,lo Further, it was noted that while the use of prolonged topical corticosteroid is known to cause proliferation of fungi, 13% of our cases had a history of corticosteroid use. It was also observed that though the range of time required for symptomatic relief was the same both in the monotherapy and combined therapy groups the mean time to relief was significantly different between the two groups (p < 0.05). This indicates that monotherapy with 0.3% ofloxacin is a better alternative for the treatment of bacterial keratitis than fortified therapy as regards symptomatic relief. Moreover, monotherapy with a drug which is already commercially available in a prepared form is preferable to having the drugs prepared.
O'Brien et al? found that over 35% of eyes healed within 7 days in both the ofloxacin and combined tobramycin and cefazolin groups. However, none of our cases showed resolution prior to 10 days. This could be attributed to the fact that their study included less severe cases while our cases were moderately severe. But on the 14th day complete resolution was observed in 53% and 40% of our ofloxacin group and control group respectively. This does not concur with the findings of the Ofloxacin Study Groups who observed resolution in 62% and 68% of cases on the 14th day. As regards overall healing, our results were similar to those of O'Brien et aI? at 4 weeks: 93% resolution in the ofloxacin group and 87% in the control group compared with 89% and 86% respectively in O'Brien et al.' s series. Given the aetiological variation and severity of the ulcer in our study, our findings cannot be compared with American studies. But they suggest that the more severe the ulcer, the longer the duration of healing despite maximum effective therapy. Finally, neither visual acuity improvement nor sequelae such as corneal opacity showed a statistically significant difference between the two groups.
In earlier studies, the percentage of culture negativity has been reported 7 , 9 , lO and found to be of varying frequency. But to make the study more meaningful we included the culture-positive cases only. Further, previous authors have commented on the non-efficacy of ofloxacin against streptococci, which is a major concern. 8 , 1 l However, no comment can be given at this time as no cases of streptococcal ulcer were identified in the present study.
Conclusions
In summary, monotherapy with 0.3% ofloxacin drops for treating bacterial keratitis should be encouraged and can be tried as a first-line drug for all cases of bacterial keratitis. Further, it offers several advantages over combined fortified therapy, such as being a single agent convenient for the patient to apply, commercially available, stable at room temperature 7 and does not require additional formulations thus eliminating potential contamination of the drop. However, as with all antibiotics, the factor of development of resistance over time should be kept in mind.
